REHOVOT, Israel and WILMINGTON, Del., Nov. 05, 2020 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102). Ayala’s lead product candidate, AL101, is currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations (ACCURACY).
Investors
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
Julie.seidel@sternir.com
Ayala Pharmaceuticals
+1-857-444-0553
info@ayalapharma.com
Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102). Ayala’s lead product candidate, AL101, is currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations (ACCURACY).
Investors
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
Julie.seidel@sternir.com
Ayala Pharmaceuticals
+1-857-444-0553
info@ayalapharma.com
